Search Results

Strategic collaboration to leverage BigHat’s AI/ML (Artificial Intelligence / Machine Learning) guided Milliner™ platform to design high-quality next-generation protein therapeutics.

AbbVie Inc. (NYSE: ABBV) and BigHat Biosciences, today announced a research collaboration to discover and develop next-generation therapeutic antibodies in oncology and neuroscience.

BigHat Biosciences, Inc. today announced a collaboration with Merck, known as MSD outside of the United States and Canada, to apply the company’s technology to design candidates for up to three drug discovery programs.

BigHat Biosciences , a biotechnology company designing safer, more effective next-generation antibody therapies for patients using machine learning and synthetic biology, today announced that Rob Chess has been elected to BigHat’s board of directors.

BigHat Biosciences will team up with Merck to design candidates for three drug discovery programs backed by the company’s proprietary AI technology platform.

BigHat Biosciences, Inc., a biotechnology company with an artificial intelligence/machine learning-guided antibody discovery and development platform, today announced the successful completion of the first stage of a previously undisclosed research collaboration and licensing agreement with Amgen applying BigHat’s platform for multi-objective optimization of a next-generation antibody.

BigHat Biosciences, a biotechnology company developing safer, more effective antibody therapies for patients using machine learning and synthetic biology, today announced it has raised a $75 million Series B funding round.

BigHat Biosciences, Inc., a biotechnology company developing safer, more effective next-generation antibody therapies for patients using machine learning and synthetic biology, today announced the acquisition of Frugi Biotechnology, a biotechnology company developing cost-effective and high-quality cell-free protein synthesis (CFPS) technology.